NYSE:JNJ - New York Stock Exchange, Inc. - US4781601046 - Common Stock - Currency: USD
JOHNSON & JOHNSON
NYSE:JNJ (1/24/2025, 8:04:00 PM)
After market: 146.99 +0.17 (+0.12%)146.82
+0.18 (+0.12%)
The current stock price of JNJ is 146.82 USD. In the past month the price increased by 1.07%. In the past year, price decreased by -7.95%.
These S&P500 stocks are moving in today's session
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here.
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 77.23 | 745.61B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 29.42 | 390.70B | ||
MRK | MERCK & CO. INC. | 16.06 | 241.71B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.13 | 214.16B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.4 | 199.87B | ||
PFE | PFIZER INC | 10.11 | 147.85B | ||
SNY | SANOFI-ADR | 12.5 | 131.58B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 51 | 121.02B | ||
ZTS | ZOETIS INC | 29.27 | 76.07B | ||
GSK | GSK PLC-SPON ADR | 8.28 | 69.92B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 21.65 | 41.18B | ||
TEVA | TEVA PHARMACEUTICAL-SP ADR | 7.8 | 24.56B |
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 131,900 full-time employees. The firm's primary focus is products related to human health and well-being. The company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).
JOHNSON & JOHNSON
One Johnson & Johnson Plaza
New Brunswick NEW JERSEY 08933 US
CEO: A. Gorsky
Employees: 131900
Company Website: https://www.jnj.com/
Investor Relations: https://www.investor.jnj.com
Phone: 17325242455
The current stock price of JNJ is 146.82 USD.
The exchange symbol of JOHNSON & JOHNSON is JNJ and it is listed on the New York Stock Exchange, Inc. exchange.
JNJ stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for JNJ, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of JNJ.
JNJ has a dividend yield of 3.38%. The yearly dividend amount is currently 4.46.
The PE ratio for JNJ is 14.7. This is based on the reported non-GAAP earnings per share of 9.99 and the current share price of 146.82 USD.
The outstanding short interest for JNJ is 0.68% of its float.
ChartMill assigns a technical rating of 1 / 10 to JNJ. When comparing the yearly performance of all stocks, JNJ is a bad performer in the overall market: 78.16% of all stocks are doing better.
ChartMill assigns a fundamental rating of 6 / 10 to JNJ. JNJ has an excellent profitability rating, but there are some minor concerns on its financial health.
Over the last trailing twelve months JNJ reported a non-GAAP Earnings per Share(EPS) of 9.99. The EPS increased by -4.22% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 16.74% | ||
ROA | 8.24% | ||
ROE | 20.93% | ||
Debt/Equity | 0.47 |
ChartMill assigns a Buy % Consensus number of 75% to JNJ. The Buy consensus is the average rating of analysts ratings from 30 analysts.
For the next year, analysts expect an EPS growth of 7.04% and a revenue growth 2.48% for JNJ